# Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

> **NCT00423254** · PHASE1 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 12 (actual)

## Conditions studied

- Ovarian
- Melanoma
- Renal
- Prostate
- Colorectal
- Endometrial Carcinoma
- Cervical Carcinoma
- Testicular Cancer
- Thyroid Cancer
- Small Cell Lung Carcinoma
- Mesothelioma
- Breast Carcinoma
- Esophageal Carcinoma
- Gastric Cancer
- Pancreatic Carcinoma
- Neuroendocrine Cancer
- Liver Cancer
- Gallbladder Cancer
- Biliary Tract Cancer
- Anal Carcinoma
- Bone Sarcomas
- Soft Tissue Sarcomas
- Carcinoma of Unknown Origin, Primary

## Interventions

- **BIOLOGICAL:** PSMA/PRAME
- **BIOLOGICAL:** PSMA/PRAME

## Key facts

- **NCT ID:** NCT00423254
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-09
- **Final completion:** 2009-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423254, "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00423254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*